Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Combretastatin A1 Diphosphate||OXi4503|OXi-4503|CA1P||Combretastatin A1 Diphosphate (OXi4503) is a vascular disrupting agent that causes microtubule instability, resulting in blood vessel collapse and decreased tumor growth (PMID: 20974154, PMID: 26751478, PMID: 32236943).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||head and neck squamous cell carcinoma||not applicable||Combretastatin A1 Diphosphate||Preclinical - Cell line xenograft||Actionable||In a preclinical study, treatment with OXi4503 resulted in increased tumor cell necrosis and decreased tumor growth and extended median survival in cell line xenograft models of head and neck squamous cell carcinoma (PMID: 26751478).||26751478|
|Unknown unknown||acute myeloid leukemia||not applicable||Combretastatin A1 Diphosphate||Phase I||Actionable||In a Phase I study, OXi4503 demonstrated safety and preliminary efficacy in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), resulting in one complete response and one partial response among 14 patients, with four patients demonstrating stable disease (PMID: 32236943).||32236943|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02576301||Phase Ib/II||Combretastatin A1 Diphosphate Combretastatin A1 Diphosphate + Cytarabine||Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS||Recruiting|